HER2-positive recurrent, MBC or unresectable locally advanced BC; patients had received a prior anti-HER2 agent and chemotherapy (prior taxane was not required) and had progressed on or after the most recent treatment or within 6 mo of completing adjuvant therapy. This evidence concerns the gene ERBB2 and breast cancer.